About 525,000 more deaths occurred among US adults in 2023 than would be expected had pre-2010 mortality trends continued.

Finerenone (Kerendia) is thought to work by inhibiting inflammation that can cause kidney damage, according to Drugs.com. The ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure ...

Dapagliflozin effectively treats fatty liver disease (MASH), reducing liver fat and scarring. Black patient involvement in ...

Management of older adults with type 2 diabetes and chronic kidney disease is complex. These individuals often have multiple comorbidities, take several medications, and are at increased risk of ...

A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

The American College of Lifestyle Medicine (ACLM) has published the first clinical practice guideline to put lifestyle ...

Learn how SGLT2 inhibitor dapagliflozin improves MASH outcomes, with potential clinical use beyond diabetes care.

Precision medicine and phenotyping help tailor treatments to individual patient profiles.